Introduction
Lumbar spinal stenosis (LSS) is a common degenerative condition that causes significant pain, disability, functional impairment, and diminished quality of life. [1] [2] [3] [4] [5] The clinical feature most commonly attributed to LSS is neurogenic claudication that involves leg symptoms encompassing the buttocks, groin, and anterior thigh, as well as radiating pain down the posterior aspect of the leg to the feet. 3, 6 The discomfort associated with LSS is often described as a cramping or burning feeling. Symptoms of neurogenic claudication can be distributed unilaterally or bilaterally, and the patient may suffer concomitant back pain, although leg pain and discomfort are usually more bothersome. 7 A distinguishing clinical attribute of neurogenic claudication is its relationship to the patient's posture, where lumbar extension increases and flexion decreases pain onset and severity. Symptoms progressively worsen when standing or walking, and are relieved by sitting and bending forward. In addition to the cardinal clinical feature of neurogenic claudication, patients often complain of symptoms that are more radicular in nature, with sharp lower-extremity pain. Leg pain is described as severe and radicular in distribution, and almost always presents with postural aggravation during lumbar extension. 6, 8 LSS is the most common indication for spine surgery in older adults.
Conservative medical management of chronic spinal pain disorders, including LSS, has increasingly included the prescription of opioid-based analgesics. [9] [10] [11] This recommendation has been based on the belief that these medications can relieve pain and improve function and quality of life in selected patients. 12 In fact, opiates have become the most commonly prescribed class of drug for back pain, based on insurance-claim data. 13 Additionally, it has been estimated that more than half of regular opioid users report back pain as a primary complaint. 14 Unfortunately, despite initial enthusiasm for opioid therapy, it has only recently been demonstrated that opioid analgesics offer little clinical benefit by way of pain reduction or functional improvement in patients with chronic musculoskeletal pain, including LSS. [15] [16] [17] [18] [19] [20] Moreover, the odds of an opioid-related adverse event are three times that compared to placebo among older adults with musculoskeletal pain. 20 Specifically, Markman et al 19 failed to demonstrate any clinical benefit of opiates in older patients experiencing neurogenic claudication secondary to LSS.
Based on emerging evidence raising concerns over the ineffectiveness and possible hazards of opioid medications in the treatment of chronic low-back and leg pain, the British National Institute for Health and Care Excellence updated their recommendation for the assessment and management of low-back pain and sciatica. 21 They concluded, "Do not offer opioids for managing low back pain". Consequently, there is an urgent need to reverse the trend in opioid prescribing being a primary strategy for patients with LSS.
There is a growing body of published literature to support the safety and effectiveness of interspinous process decompression (IPD) with stand-alone interspinous spacers in the treatment of moderate LSS. 22, 23 Spacers provide immediate symptom amelioration by serving as a spinal extension blocker to prevent the repetitive compression of neurovascular elements during back extension that is the primary source of LSS symptoms. Clinical follow-up from a US Food and Drug Administration (FDA) investigational device exemption (IDE) randomized controlled trial of the Superion device extends to 5 years of published findings. 24 Durable and clinically significant improvements have been demonstrated following spacer implantation in conditionspecific impairment, leg-and back-pain severity, functional disability, and health-related quality of life. The degree of clinical improvement achieved with spacers appears to be strikingly similar to the improvement achieved with decompressive laminectomy, long considered the "gold standard" for surgical treatment of LSS. 25 Owing to the magnitude, stability, and longevity of clinical benefit observed among LSS patients treated with IPD, we have undertaken additional analyses of ancillary variables in our IDE trial that may have a direct impact on health care utilization. This report examines and characterizes the opioid-medication-usage patterns among patients treated with stand-alone IPD through 5 years of postoperative follow-up.
Methods
Type, dosage, and duration of opioid medications through 5 years of postoperative follow-up were obtained from the Superion Indirect Decompression system (Vertiflex Inc., Carlsbad, CA, USA) treatment arm of a randomized controlled FDA IDE noninferiority trial comparing two interspinous spacers. Medication-prescribing history was documented and validated via electronic data-capture methods for all treated patients during their enrollment and participation as study subjects.
This multicenter trial evaluated the use of stand-alone IPD in the treatment of subjects aged 45 years or older with moderate symptoms of intermittent neurogenic claudication, secondary to a diagnosis of moderate degenerative LSS at one or two contiguous levels from L1 to L5. A total of 391 subjects met the trial-eligibility criteria and were randomized to treatment. The Superion was approved by the FDA in 2015 for commercial distribution based on the 2-year primary end-point analysis. 23 Additionally, condition-specific clinical outcomes have been reported through 5 years of follow-up. 24, 26, 27 Inasmuch as the control device (X-Stop IPD; Medtronic, Minneapolis, MN, USA) is no longer commercially available, the current opioid-medication analysis was restricted exclusively to the Superion arm of the trial.
This IDE trial complied with all US regulatory requirements and was approved by the institutional review board at each participating site, and patients provided written informed consent before any study-related procedures were performed. The trial was conducted in accordance with the Declaration of Helsinki and prospectively registered at ClinicalTrials.gov (NCT00692276).
Based on opioid-medication start date and duration of use, the prevalence of subjects using opiates was clas- 
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Opioid reduction with interspinous spacer treatment sified by postoperative follow-up in the same intervals as other previously reported clinical outcomes from this trial (ie, baseline, 6 weeks, and 3, 6, 12, 18, 24, 36, 48, and 60 months). Previous (ie, prestudy) opioid-medication use prior to a subject's enrollment in the trial was also captured based on entrance-eligibility interviews that queried medication history for LSS.
Our primary analysis included all 190 patients randomized to receive the Superion device to determine opioid-medication prevalence. At each follow-up, medication-usage data were provided only for subjects free of reoperation or revision at the index surgical level. Sample sizes were 190 (baseline), 181 (6 weeks), 173 (3 months), 174 (6 months), 163 (12 months), 150 (18 months), 150 (24 months), 125 (36 months), 106 (48 months), and 107 (60 months). A second subgroup analysis was also undertaken after excluding all subjects that had initiated opiates after surgery (n=92). In the remaining subgroup of 98 subjects, we determined opioid-medication prevalence in the same manner among subjects with a history of opioid use for LSS. Sample sizes in this subgroup were 98 (baseline), 90 (6 weeks), 87 (3 months), 87 (6 months), 84 (12 months), 74 (18 months), 79 (24 months), 66 (36 months), 54 (48 months), and 55 (60 months). Table 1 provides opioid-medication types and frequency of use among all study subjects through 60 months of clinical follow-up.
Results
Among all study subjects, there was a marked yearon-year decrease in the proportion of patients prescribed opioid medications to manage LSS symptoms after Superion implantation (Figure 1 ). At baseline, almost 50% (94 of 190) of subjects were using opioid medication, with a spike in opioid use (64.1%, 116 of 181) at the 6-week follow-up interval. After this early postoperative interval, there was a sharp diminution in opioid-medication prevalence from 25.2% (41 of 163) at 12 months to 13.3% (20 of 150) at 24 months to 7.5% (8 of 107) at 60 months. Overall, between baseline and 5 years, there was an 85% decrease in the proportion of subjects using opioids.
A similar pattern of decreased opioid-medication usage was also observed among the subgroup of subjects with a history of opiates at trial entry (Figure 2 ). At enrollment, 67.3% (66 of 98) reported prior opioid usage to manage LSS symptoms. By week 6, usage had dropped to 48.9% (44 of 90). Opioid-medication prevalence was 27.4% (23 of 84) at 12 months, 15.2% (12 of 79) at 24 months, and 9.1% (5 of 55) at 60 months. In this subgroup, between baseline and 5 years, there was an 82% decrease in the proportion of subjects using opioids.
Discussion
It has recently been reported in patients aged ≥65 years with a new-back-pain visit that those filling two or more opioid prescriptions within 90 days of the visit had similar backrelated outcomes, but an increased likelihood of filling opioid prescriptions 18-24 months later, compared with matched patients who did not fill early opioid prescriptions. 28 This finding suggests a dangerous opioid recidivism and underscores the need to reverse the trend in opioid-prescribing patterns among older patients with musculoskeletal pain syndromes, including LSS.
The large multicenter Spine Patient Outcome Research Trial (SPORT) trial of LSS reported opioid-usage prevalence of 27% at baseline prior to laminectomy. 29 In our IDE trial, we found that ~35% of patients randomized to receive Superion had a history of opioid use at enrollment in the study (Figure 1) . We also noted that study subjects were perfunctorily prescribed opiates in the immediate postoperative period, raising the prevalence to 64% within 6 weeks of surgery.
However, after the early postsurgical period, we identified a marked diminution in the prevalence of opioid usage, dropping to 25% at 12 months and 13% by 24 months. These results compare favorably with opioid-prevalence estimates associated with other interventions for LSS. For example, in a randomized trial of repeated epidural steroid injections for LSS, Friedly et al 30 reported baseline opioid-usage prevalence of 38% and 12-month prevalence of 41%, confirming and extending previous research demonstrating lack of long- Our results are also somewhat better than those realized after decompressive laminectomy. In a randomized controlled IDE trial, Schmidt et al 33 reported prestudy opioid-usage prevalence of 31%, spiking postsurgically to 67%, then decreasing to 19% at 12 months, and 23% by 24 months following laminectomy. In our trial, the prevalence of opioid usage continued to drop precipitously to 7.5% by 60 months. It is unknown whether postlaminectomy patients enjoy a similarly rapid decrease in opioid usage with longer-term follow-up. However, if laminectomy-associated instability ensues and symptoms reemerge, revision to fusion may be necessary, requiring reestablishment of opiate therapy.
Many patients expect spine surgery to eliminate the need for opioids. Indeed, prior to lumbar fusion surgery, over 90% of patients surveyed considered continued dependence on opioids neither an expected nor acceptable outcome. 34 In a retrospective cohort study of 2,492 patients having lumbar fusion surgery for degenerative conditions, including LSS, Deyo et al 35 found that more patients received long-term opioids postoperatively (n=1,094) than preoperatively (n=1,045). Additionally, opioid-naïve patients had a substantial risk of initiating long-term use.
Increasing utilization of opioid medications as part of a treatment regime to manage chronic pain has been associated with drug misuse, complications, and fatal overdoses. 36 This problem is even more acute in older adults, who are more susceptible to the adverse effects of opioids, such as disorientation, syncope, and falls. 37 We found that stand-alone IPD in older patients with LSS substantially reduced the need for opioid medication through 5 years of postoperative followup. This finding mirrors a similarly notable reduction in need for reoperation or revision following IPD. We previously reported that 75% (142 of 190) of IPD subjects were free of reoperation at their index level through 5 years of follow-up. 24 Importantly, among the 48 spacer subjects that had a reoperation, 38 (79%) subjects underwent their reoperation within the initial 24 months of follow-up. Only a single reoperation occurred during the fifth year of observation, suggesting a continuously decreasing risk of revision surgery with time. The compilation of results from this IDE trial demonstrates long-term durable improvements in condition-specific pain and functional outcomes, as well as marked reductions in the need for opioid medication and revision surgery with IPD through 5 years of follow-up.
This study has several limitations. In the absence of a nonsurgical control, we were unable to estimate the 
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Opioid reduction with interspinous spacer treatment comparative natural history of opioid usage among LSS patients treated conservatively. Although medication prescribing was captured on a compulsory basis for all study subjects, the trial was not designed to evaluate opioid usage as a primary or secondary outcome. As an ancillary variable, data collection methods lacked a standardized methodology to quantify opioid usage. Consequently, our post hoc analysis was constrained to prevalence estimates within specified postoperative follow-up intervals and limited only to those patients who remained implanted with the study device and who were free of a reoperation at the index surgical level.
Conclusion
Stand-alone IPD is associated with a marked and sustained decrease in the need for opioid medications to manage symptoms related to LSS. This finding extends previous results showing long-term sustained clinical improvements, a reduction in symptoms of neurogenic claudication, and a decreasing requirement for revision surgery in this population.
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